{
    "medicine_id": "c4079c3eb8942a538a384ba271688f7428a459e6",
    "platform_id": "DB00965",
    "metadata": {
        "name": "Ethiodol 475 mg 1mL Injection",
        "composition": "475 mg 1mL Ethiodized oil",
        "clinical_particulars": {
            "therapeutic_indications": "For use as a radio opaque medium for hysterosalpingography and lymphography and as an antineoplastic agent when part of the iodine is 131 I It is also used in follow up imaging for chemoembolization",
            "contraindications": {
                "disease": "Intravenous LD50 in dog is 1580mg kg Symptoms of overdose include dyspnea and change in clotting factors",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "There has been little detailed investigation of the metabolic fate of ethiodized oil in either man or animals However the fate of ethiodized oil following Iymphangiography in dogs has been reported Koehler i et al i employed I sup 131 sup tagged ethiodol for lymphangiography in dogs and analyses of individual organs at various time intervals were done The investigators reported an average of only 25 of the injected medium was retained in the lymphatics at the end of three days An average of 50 was recovered from the lungs They found the remainder of injected activity was fairly uniformly distributed throughout the body Urinary excretion in the form of inorganic iodine was revealed as the chief mode of iodine loss from the system",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00041",
                        "description": "The risk of a hypersensitivity reaction to Ethiodized oil is increased when it is combined with Aldesleukin"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}